The Optispan Podcast with Matt Kaeberlein

Links to All Articles Mentioned:
https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-riskshttps://www.fda.gov/media/174456/downloadRFK Jr. just appeared on the Joe Rogan podcast and peptides were front and center. Dr. Matt Kaeberlein breaks down the conversation in real time, fact-checking claims about peptide efficacy, FDA regulation, and the growing black market for compounded peptides.What does the science actually say? What did RFK get right and where did the conversation miss the mark? Dr. Kaeberlein cuts through the noise with a scientist's lens, covering everything from BPC-157 to GLP-1 agonists to the FDA's Category 2 bulk drug substances list.If you're navigating the peptide space and want clarity over hype, this one's for you.Timestamps:00:00 — Intro & Episode Overview01:06 — RFK on Joe Rogan: The Peptide Conversation Begins02:06 — First Fact Check: "We Know Peptides Work"03:50 — GLP-1 Agonists: The Exception, Not the Rule05:05 — RFK's Personal Peptide Experience06:32 — The FDA's Bulk Drug Substances List Explained08:32 — FDA Category 2: What It Actually Means09:21 — The Peptides That Were Banned From Compounding10:18 — Did the FDA Consider Safety? Here's What the Data Says12:03 — Real Cases of People Harmed by Compounded Peptides13:40 — Can the FDA Consider Efficacy? Reading Directly From the Guidelines15:44 — The Peptide Black Market: How It Emerged17:54 — Will Reversing the Ban Actually Fix the Problem?19:20 — RFK's Push to Move 14 Peptides Back to the Bulk List20:16 — Dr. Kaeberlein's Take: Informed Patient Access Matters21:51 — Who Created the Black Market?22:46 — What Would Actually Help: Funding Real Clinical Trials23:36 — Final Thoughts & Call to Action

What does over 18 months of precision medicine actually look like in practice? In this episode of the Optispan Success Story Series, Dr. Matt Kaeberlein sits down with Carlos Pinto, a tech executive and early Optispan client, to trace his longitudinal health journey from metabolic warning signs to measurable, sustained transformation. Carlos shares how a decade of overlooked biomarkers, a post-pandemic health decline, and a single panic attack became the catalyst for a data-driven approach to his own biology. Together, he and Dr. Kaeberlein review real DEXA, lipid, metabolic, and environmental biomarker data, unpacking what moved the needle, what didn't, and why the answer was rarely simple. This conversation is a candid look at what it means to become your own best health advocate, not through quick fixes, but through personalized, longitudinal learning.Timestamps:0:00 – Cold open & highlights0:50 – Welcome & Carlos's background in tech leadership2:15 – How career ambition displaced health in his 20s and 30s3:39 – A panic attack as the turning point: connecting mental and physical health4:24 – A previous medical wellness program: what worked and what was missing6:34 – Arriving at OptiSpan: intention, mindset, and expectations7:15 – Gateway Day: comprehensive baseline testing and initial surprises8:51 – Early metabolic lessons: CGM data, glucose spikes, and dawn effect11:32 – Confronting white coat hypertension with 78 data points13:28 – How stress, sleep, and nutrition interact to drive metabolic dysfunction15:44 – Personal experimentation as methodology: berberine, time-restricted eating, and fish17:09 – Mercury toxicity from fish consumption: a case study in biomarker surveillance18:33 – Stress management protocols: walking, meditation, and measurable outcomes19:49 – Statin introduction: the role of medication as a tool, not a failure20:27 – DEXA results: visceral fat reduction, body fat loss, and lean mass gain24:17 – Lipid profile transformation: ApoB from ~115 to 70, LDL from 160 to 7425:57 – A1C trajectory and the complexity of glucose optimization30:01 – Reframing medication: proactive use vs. reactive disease management31:29 – Mercury biomarker deep dive: from 2.4 to 16 and back to 232:21 – Goals for the future: sustainability, muscle retention, and mental clarity36:30 – Lineage biological age algorithm: from mortality risk of 54 to 5239:27 – Closing reflections: health as a lifelong trajectory, not a program

Peptides are everywhere in longevity and functional medicine, but what does the law actually say? In this episode, Dr. Matt Kaeberlein breaks down what a peptide is and the complex regulatory landscape governing peptides in the United States, from FDA approval frameworks to the legal gray zones surrounding compounding pharmacies and unapproved substances.Drawing on the Federal Food, Drug, and Cosmetic Act and real-world enforcement cases, this episode offers a clear-eyed, non-judgmental examination of what is legal, what is tolerated, and what carries genuine risk for physicians, pharmacies, and patients alike. An essential listen for anyone navigating the rapidly evolving world of peptide therapeutics.Timestamps:00:00 — The Tailor Made Compounding Case: Criminal Prosecution & FDA-Flagged Peptides00:54 — Welcome & Episode Overview: The Regulatory Environment of Peptides01:36 — What Is a Peptide? Definitions and Biological Context03:26 — Are Peptides Regulated by the FDA?04:16 — Two Regulatory Frameworks: Biologics vs. Chemically Synthesized Drugs05:17 — The Food, Drug, and Cosmetic Act: Which Peptides Fall Under It?06:11 — Why Two Frameworks Exist: A Brief Legislative History07:06 — The Core Rule: FDA Approval vs. Unapproved Status07:54 — FDA-Approved Peptides: What Can Legally Be Prescribed09:11 — Compounding Pharmacies: When Is It Legal?10:01 — The Unapproved Peptide Bucket: A Long List10:55 — Legal Status of Unapproved Peptides Under U.S. Law12:34 — The Bulk Drug Substances List: What It Is and What It Isn't14:11 — FDA's "Significant Safety Risk" Flagged Peptides15:04 — Why Some Pharmacies Still Compound Unapproved Peptides16:44 — The Gray Area: Speeding Analogies and Cultural Norms17:38 — Degrees of Risk: Formulation, Approval Status, and Data Quality18:38 — Who Bears Legal Liability? Pharmacies, Physicians, and Patients19:39 — The Tailor Made Compounding Case: DOJ Action and Criminal Conviction20:34 — Risk to Physicians and Patients Summarized21:24 — Self-Sourcing Peptides Online: What Consumers Should Know22:14 — Prescription Drugs Without a Prescription: Legal Nuance23:06 — Final Thoughts: The State of Peptide Medicine Today23:58 — How Enforcement Norms Can Shift and Why It Matters Now24:48 — Questions to Ask Yourself: Risk Tolerance and Physician Choice25:21 — An Informed Consent Framework for Peptide Use26:03 — Coming Up: Individual Peptide Deep-Dives in Future Episodes

On this episode, Dr. Matt Kaeberlein is joined by Noah Neiman, co-founder of Rumble Boxing and founder of Knuckle Therapy. From panic attacks and rock bottom to building global fitness brands, Noah and Matt explore the profound connection between physical training and mental resilience. Noah shares how structured movement became the foundation for managing ADHD, anxiety, and depression, and why the discipline of fight training translates directly into how we navigate life's hardest moments. A candid conversation on the neuroscience of presence, the therapeutic power of service to others, and what it truly means to train for longevity, in the ring and beyond.Timestamps:00:00 — Introduction & Cold Weather in New York01:04 — Pittsburgh Roots, Sports, and Life Metaphors02:22 — How Training Saved Noah's Life03:05 — ADHD, Physical Control, and Emotional Regulation04:36 — Early Influences: Boxing Gyms, Body for Life, and Therapy06:28 — Football, Identity, and Taking Control of the Body07:02 — College, Jiu-Jitsu, and Finding Purpose08:08 — Anxiety, Depression, and the Power of Presence09:22 — What "Training" Really Means: Sleep, Nutrition, and Mindset10:36 — How You Train Is How You Fight Is How You Live13:30 — The Turning Point: Giving to Others as Therapy14:10 — Selling Drugs, Materialism, and Misery15:23 — Muhammad Ali, Service, and Spiritual Rent17:23 — Failing Upwards: The Road to Barry's Bootcamp19:46 — Warren Stout, Jiu-Jitsu, and Rebuilding After Near-Overdose21:19 — The Craigslist Apartment and Moving to New York22:27 — Walking Into Barry's Bootcamp for the First Time25:44 — Vampire Fitness Hour: Building a Brand from One Class27:47 — Teaching Through Panic Attacks and Overcoming Them28:57 — Medication, Anxiety, and Finding the Root Cause31:12 — The Tattoo, King Henry VI, and "Fearless Minds"32:30 — The Birth of Rumble Boxing36:54 — Co-founding Rumble with Eugene Ram38:09 — Pandemic, Selling Rumble, and What Comes Next40:07 — Launching The Pack: Three Dogs, Three Modalities47:07 — Knuckle Therapy: Honoring Oz and Building a Brand52:55 — A Typical Week: Exercise, Walking, and Movement55:17 — Training at Henzo Gracie's and Teaching Daily57:03 — Recovery, Injury Prevention, and Longevity at 4101:02:37 — Nutrition: Eating a Lot, Eating Clean01:06:46 — Sleep, Balance, and Living in the Extremes01:11:43 — The Most Unexpected Part of the Journey01:16:24 — Advice for Anyone Going Through It01:19:46 — Choose Love, Not Fear: Closing Thoughts

The longevity supplement industry is full of hype, marketing claims, and questionable science. In this episode, Matt breaks down 13 popular supplements through an evidence-based lens.Subscribe for more evidence-based longevity content.
Timestamps:0:00 - Introduction: 13 Supplements Ranked, 1:41 - How the Tier List Works (Strong, Good, Promising, Overhyped, Avoid), 2:27 - Fucoidin, 8:04 - Fisetin, 8:54 - Lithium Orotate, 12:34 - Resveratrol, 13:24 - Creatine, 14:58 - CoQ10, 15:53 - SS Peptides (SS-31/Elamipretide), 24:09 - Proprietary "Anti-Aging" Blends, 24:55 - NAD+ Precursors, 27:17 - Omega-328:47 - Vitamin D, 29:24 - Fatty 15 (Pentadecanoic Acid), 31:01 - Urolithin A, 32:31 - Final Rankings: All 13 Supplements Ranked 1-13, 34:41 - Closing Thoughts